Su, Yung-YehYung-YehSuChiang, Nai-JungNai-JungChiangLi, Chung-PinChung-PinLiYen, Chia-JuiChia-JuiYenSHIH-HUNG YANGChou, Wen-ChiWen-ChiChouChen, Jen-ShiJen-ShiChenChiu, Tai-JanTai-JanChiuChen, Yen-YangYen-YangChenChuang, Shih-ChangShih-ChangChuangBai, Li-YuanLi-YuanBaiChiu, Chang-FangChang-FangChiuPeng, Cheng-MingCheng-MingPengChan, De-ChuanDe-ChuanChanChiu, Sz-ChiSz-ChiChiuYang, Yi-HsinYi-HsinYangShan, Yan-ShenYan-ShenShanChen, Li-TzongLi-TzongChen2022-10-312022-10-3120222234-943Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/624302This multicenter, real-world cohort study aimed to evaluate the effectiveness of early cumulative dose administration and dosing pattern of liposomal irinotecan plus fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (mPDAC).endose escalation strategy; dose intensity; nal-IRI; pancreatic cancer; real world[SDGs]SDG3Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Studyjournal article10.3389/fonc.2022.800842358143742-s2.0-85133650814WOS:000821120600001https://api.elsevier.com/content/abstract/scopus_id/85133650814